Compounds > 3-benzyl-5-((2-nitrophenoxy)methyl)dihydrofuran-2(3h)-one
Page last updated: 2024-11-12

3-benzyl-5-((2-nitrophenoxy)methyl)dihydrofuran-2(3h)-one

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3-benzyl-5-((2-nitrophenoxy)methyl)dihydrofuran-2(3H)-one: inhibits vascular endothelial cell apoptosis and senescence; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID16216349
CHEMBL ID238943
SCHEMBL ID17595228
MeSH IDM0551702

Synonyms (19)

Synonym
CHEMBL238943
3-benzyl-5-((2-nitrophenoxy)methyl)dihydrofuran-2(3h)-one
S8317
SCHEMBL17595228
3bdo ,
3-benzyl-5-((2-nitrophenoxy) methyl)-dihydrofuran-2(3h)-one
3bdo, >=98% (hplc)
890405-51-3
HY-U00434
CS-0035372
BCP29764
CCG-267777
D70053
3-bdo
AS-55804
3-benzyl-5-[(2-nitrophenoxy)methyl]oxolan-2-one
AKOS037644985
PD078299
AKOS040741002
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (12)

Assay IDTitleYearJournalArticle
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID305174Inhibition of FGF2 deprivation-induced integrin beta-4 expression in vascular endothelial cells at 40 ug/ml after 24 hrs relative to control2007Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2
A novel butyrolactone derivative inhibited apoptosis and depressed integrin beta4 expression in vascular endothelial cells.
AID305176Inhibition of FGF2 deprivation-induced ROS level in vascular endothelial cells at 30 ug/ml after 24 hrs relative to control2007Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2
A novel butyrolactone derivative inhibited apoptosis and depressed integrin beta4 expression in vascular endothelial cells.
AID305170Inhibition of DNA fragmentation in vascular endothelial cells at 40 ug/ml after 24 hrs2007Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2
A novel butyrolactone derivative inhibited apoptosis and depressed integrin beta4 expression in vascular endothelial cells.
AID305169Prevention of FGF2 deprivation-induced reduction of vascular endothelial cell viability after 24 hrs by MTT assay2007Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2
A novel butyrolactone derivative inhibited apoptosis and depressed integrin beta4 expression in vascular endothelial cells.
AID305168Prevention of serum deprivation-induced reduction of vascular endothelial cell viability after 24 hrs by MTT assay2007Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2
A novel butyrolactone derivative inhibited apoptosis and depressed integrin beta4 expression in vascular endothelial cells.
AID305178Prevention of FGF2 deprivation-induced reduction of vascular endothelial cell viability after 48 hrs by MTT assay2007Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2
A novel butyrolactone derivative inhibited apoptosis and depressed integrin beta4 expression in vascular endothelial cells.
AID305172Inhibition of FGF2 deprivation-induced vascular endothelial cell apoptosis assessed as apoptotic cell proportion at 40 ug/ml after 24 hrs by TUNEL assay2007Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2
A novel butyrolactone derivative inhibited apoptosis and depressed integrin beta4 expression in vascular endothelial cells.
AID305173Inhibition of serum deprivation-induced integrin beta-4 expression in vascular endothelial cells at 40 ug/ml after 24 hrs relative to control2007Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2
A novel butyrolactone derivative inhibited apoptosis and depressed integrin beta4 expression in vascular endothelial cells.
AID305171Inhibition of serum deprivation-induced vascular endothelial cell apoptosis assessed as apoptotic cell proportion at 40 ug/ml after 24 hrs by TUNEL assay2007Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2
A novel butyrolactone derivative inhibited apoptosis and depressed integrin beta4 expression in vascular endothelial cells.
AID305177Prevention of serum deprivation-induced reduction of vascular endothelial cell viability after 48 hrs by MTT assay2007Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2
A novel butyrolactone derivative inhibited apoptosis and depressed integrin beta4 expression in vascular endothelial cells.
AID305175Inhibition of serum deprivation-induced ROS level in vascular endothelial cells at 30 ug/ml after 24 hrs relative to control2007Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2
A novel butyrolactone derivative inhibited apoptosis and depressed integrin beta4 expression in vascular endothelial cells.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (15.38)29.6817
2010's8 (61.54)24.3611
2020's3 (23.08)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.59

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.59 (24.57)
Research Supply Index2.64 (2.92)
Research Growth Index5.23 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.59)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
chloroquine
Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.. chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.		2.0510aminoquinoline;
organochlorine compound;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
antirheumatic drug;
autophagy inhibitor;
dermatologic drug
pentylenetetrazole
Pentylenetetrazole: A pharmaceutical agent that displays activity as a central nervous system and respiratory stimulant. It is considered a non-competitive GAMMA-AMINOBUTYRIC ACID antagonist. Pentylenetetrazole has been used experimentally to study seizure phenomenon and to identify pharmaceuticals that may control seizure susceptibility.. pentetrazol : An organic heterobicyclic compound that is 1H-tetrazole in which the hydrogens at positions 1 and 5 are replaced by a pentane-1,5-diyl group. A central and respiratory stimulant, it was formerly used for the treatment of cough and other respiratory tract disorders, cardiovascular disorders including hypotension, and pruritis.		2.4110organic heterobicyclic compound;
organonitrogen heterocyclic compound
4-butyrolactone
4-Butyrolactone: One of the FURANS with a carbonyl thereby forming a cyclic lactone. It is an endogenous compound made from gamma-aminobutyrate and is the precursor of gamma-hydroxybutyrate. It is also used as a pharmacological agent and solvent.. tetrahydrofuranone : Any oxolane having an oxo- substituent at any position on the tetrahydrofuran ring.. gamma-butyrolactone : A butan-4-olide that is tetrahydrofuran substituted by an oxo group at position 2.		3.9110butan-4-olidemetabolite;
neurotoxin
acetylcysteine
N-acetyl-L-cysteine : An N-acetyl-L-amino acid that is the N-acetylated derivative of the natural amino acid L-cysteine.		2.0710acetylcysteine;
L-cysteine derivative;
N-acetyl-L-amino acid		antidote to paracetamol poisoning;
antiinfective agent;
antioxidant;
antiviral drug;
ferroptosis inhibitor;
geroprotector;
human metabolite;
mucolytic;
radical scavenger;
vulnerary
ex 527
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide: structure in first source. 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide : A member of the class of carbazoles that is 2,3,4,9-tetrahydro-1H-carbazole which is substituted at position 1 by an aminocarbohyl group and at position 6 by a chlorine.		2.1510carbazoles;
monocarboxylic acid amide;
organochlorine compound
sirolimus
Sirolimus: A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.. sirolimus : A macrolide lactam isolated from Streptomyces hygroscopicus consisting of a 29-membered ring containing 4 trans double bonds, three of which are conjugated. It is an antibiotic, immunosupressive and antineoplastic agent.		2.4920antibiotic antifungal drug;
cyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
organic heterotricyclic compound;
secondary alcohol		antibacterial drug;
anticoronaviral agent;
antineoplastic agent;
bacterial metabolite;
geroprotector;
immunosuppressive agent;
mTOR inhibitor
thromboplastin
Thromboplastin: Constituent composed of protein and phospholipid that is widely distributed in many tissues. It serves as a cofactor with factor VIIa to activate factor X in the extrinsic pathway of blood coagulation.		2.1510
ConditionIndicatedRelationship StrengthStudiesTrials
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.8330
Aura
[description not available]		02.4110
Absence Seizure
[description not available]		02.4110
Epilepsy
A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313)		02.4110
Seizures
Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.		02.4110
Lung Injury, Acute
[description not available]		02.1510
Endotoxemia
A condition characterized by the presence of ENDOTOXINS in the blood. On lysis, the outer cell wall of gram-negative bacteria enters the systemic circulation and initiates a pathophysiologic cascade of pro-inflammatory mediators.		02.1510
Acute Lung Injury
A condition of lung damage that is characterized by bilateral pulmonary infiltrates (PULMONARY EDEMA) rich in NEUTROPHILS, and in the absence of clinical HEART FAILURE. This can represent a spectrum of pulmonary lesions, endothelial and epithelial, due to numerous factors (physical, chemical, or biological).		02.1510
Atherogenesis
[description not available]		02.5120
Atherosclerosis
A thickening and loss of elasticity of the walls of ARTERIES that occurs with formation of ATHEROSCLEROTIC PLAQUES within the ARTERIAL INTIMA.		02.5120
Acute Confusional Senile Dementia
[description not available]		02.0710
Age-Related Memory Disorders
[description not available]		02.0710
Alzheimer Disease
A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)		02.0710
Memory Disorders
Disturbances in registering an impression, in the retention of an acquired impression, or in the recall of an impression. Memory impairments are associated with DEMENTIA; CRANIOCEREBRAL TRAUMA; ENCEPHALITIS; ALCOHOLISM (see also ALCOHOL AMNESTIC DISORDER); SCHIZOPHRENIA; and other conditions.		02.0710